- Advertise
- Contact Us
- Contribute
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
- About Us
© 2022 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
Expert Interviews
Screening for Cardiovascular Disease
January 26, 2022
Criteria and types of health care professionals who may screen patients at high risk for cardiovascular disease.
Counseling Patients on CVD Risk Factors
January 26, 2022
Recommendations for establishing relationships and talking with patients about primary and secondary prevention against cardiovascular events.
Strategies Used to Treat Hypercholesterolemia
January 14, 2022
The standard of care for managing high cholesterol levels.
Multidisciplinary Approaches to Reducing CVD Risk
January 14, 2022
The value of interdisciplinary research and multidisciplinary care of patients at high risk for cardiovascular events.
Trujillo CPP Study Review: Conclusion
December 22, 2021
Karen O. Klein, MD, leads a discussion of the Trujillo et al study on the importance of individualizing treatment decisions in girls with CPP, including factors that influence the decision to begin and cease treatment.
Trujillo CPP Study Review: Study Results
December 22, 2021
Karen O. Klein, MD, reviews data and study results from the Trujillo et al study on the importance of individualizing treatment decisions in girls with CPP.
Trujillo CPP Study Review: Overview and Baseline Characteristics
December 22, 2021
Karen O. Klein, MD, provides an overview of CPP (central precocious puberty) as well as a review of the study design and baseline characteristics from the Trujillo et al study on the importance of individualizing treatment decisions in girls with CPP.
Future Directions for the Use of Biosimilars in Diabetes
December 01, 2021
Drs Thomas C. Blevins and Diana Isaacs share insight on unmet needs and the future treatment landscape of biosimilars in the treatment of patients with diabetes.
Challenges to Biosimilar Adoption of Insulin Glargine-yfgn
December 01, 2021
Thomas C. Blevins, MD, ECNU, FACE, FNLA, leads the discussion on potential challenges to the adoption of biosimilars in clinical practice, such as for insulin glargine-yfgn in diabetes management, and discusses the importance of patient and provider education.